NEOLA.ST Neola Medical AB
- Market cap
- SEK 53.2M
- P/E
- -
- P/B
- 0.55x
- ROE
- -14.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NEOLA.ST undervalued?
Graham numberThe Graham number of Neola Medical AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neola Medical AB fundamental analysis
No fundamental analysis for Neola Medical AB yet.
Neola Medical AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neola Medical AB
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. The company was formerly known as GPX Medical …
Full company profileNeola Medical AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neola Medical AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 575K | 16.0K | 31.0K | 625K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.27M | -3.16M | -7.85M | -7.36M | -571K | -1.43M | -1.53M | -1.39M | -1.42M |
| Operating Income | -1.27M | -3.16M | -7.85M | -7.36M | -10.4M | -9.62M | -11.1M | -11.1M | -14.6M |
| EBITDA | -754K | -2.60M | -6.71M | -6.64M | -9.32M | -7.42M | -8.54M | -9.75M | -13.2M |
| Net Income | -761K | -2.61M | -6.72M | -6.65M | -10.4M | -9.01M | -10.1M | -11.0M | -14.6M |
| EPS | -0.04 | -0.15 | -0.70 | -0.37 | -0.40 | -0.16 | -0.14 | -0.14 | -0.19 |
| Balance Sheet | |||||||||
| Total Assets | 14.0M | 12.2M | 26.0M | 43.8M | 75.3M | 86.0M | 73.6M | 78.8M | 104M |
| Total Liabilities | 671K | 1.50M | 2.42M | 3.19M | 7.85M | 6.99M | 4.65M | 3.00M | 6.86M |
| Shareholders' Equity | 13.3M | 10.7M | 23.5M | 40.6M | 67.5M | 79.0M | 69.0M | 75.8M | 97.6M |
| Cash & Short-term Investments | 9.86M | 5.36M | 16.6M | 22.9M | 40.1M | 21.6M | 19.6M | 16.1M | 4.03M |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.32M | -2.07M | -6.08M | -6.93M | -8.50M | -6.54M | -10.8M | -12.0M | -11.3M |
| Capital Expenditure | 1.36M | 2.44M | 2.18M | 10.5M | 11.6M | 12.3M | 11.2M | 12.0M | 0.00 |
| Free Cash Flow | -2.67M | -4.50M | -8.25M | -17.4M | -20.1M | -18.8M | -10.8M | -21.3M | -11.3M |
| Ratios | |||||||||
| ROE | -5.7% | -24.3% | -28.5% | -16.4% | -15.3% | -11.4% | -14.6% | -14.5% | -14.9% |
| ROA | -5.4% | -21.3% | -25.9% | -15.2% | -13.7% | -10.5% | -13.7% | -14.0% | -13.9% |
| Net Profit Margin | -132.3% | -16,287.5% | -21,667.7% | -1,064.5% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Neola Medical AB dividends
Neola Medical AB has not paid dividends in the last 8 fiscal years.
Who owns Neola Medical AB
- Insiders 44.65%
- Institutions 13.98%
- Public & others 41.37%
- Shares outstanding 110M
- Free float 37.4M
Neola Medical AB company profile
- Company name
- Neola Medical AB
- Ticker
- NEOLA.ST
- ISIN
- SE0014829255
- Exchange
- Stockholm Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 9
- Fiscal year end
- December
- Address
- Ideon Gateway, Lund, Sweden, 223 63
- Website
- neolamedical.com
About Neola Medical AB
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden.
Neola Medical AB management
4- Ms. Hanna SjostromCEO & MD · born 1979
- Mr. David FolkessonChief Financial Officer · born 1980
- Ms. Sara BergstenChief Technology Officer · born 1973
- Mr. Magnus JohnssonDirector Quality Assurance & Regulatory Affairs · born 1975